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Abstract 15 
 16 
Cartilage and tendon injuries are a significant source of animal wastage and financial loss 17 
within the horse racing industry. Moreover, both cartilage and tendon have limited intrinsic capacity 18 
for self-repair, and the functionally inferior tissue produced within a lesion may reduce performance 19 
and increase the risk of re-injury. Stem cells offer tremendous potential for accelerating and 20 
improving tissue healing, and adult mesenchymal stem cells (MSC) are already used to treat 21 
cartilage and tendon injuries in horses. However, MSCs are scarce in the bone marrow isolates 22 
used, have limited potential for proliferation and differentiation in vitro and do not appear to 23 
noticeably improve long-term functional repair. Embryonic stem cells (ESC) or induced pluripotent 24 
stem (iPS) cells could overcome many of the limitations and be used to generate tissues of value for 25 
equine regenerative medicine. To date, six lines of putative ESCs have been described in the horse. 26 
All expressed stem cell-associated markers and exhibited longevity and pluripotency in vitro, but 27 
none have been proven to exhibit pluripotency in vivo. Moreover, it is becoming clear that the 28 
markers used to characterise the putative ESCs were inadequate, primarily because studies in 29 
domestic species have revealed that they are not specific to ESCs or the pluripotent inner cell mass, 30 
but also because the function of most in the maintenance of pluripotency is not known. Future 31 
derivation and validation of equine embryonic or other pluripotent stem cells would benefit greatly 32 
from a reliable panel of molecular markers specific to pluripotent cells of the developing horse 33 
embryo. 34 
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1. Potential for stem cell therapy in the horse 39 
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Injury-induced failure of horses to compete in the races for which they were bred and 41 
trained costs the racehorse industry an estimated US$6.5 billion per year [1]. Moreover, many of the 42 
more common equine athletic injuries affect musculoskeletal tissues with a limited capacity for 43 
complete functional repair (e.g. cartilage and tendon). In this respect, osteoarthritis is a frequent 44 
cause of equine lameness [2] with joint problems accounting for 15 to 25% of horses lost from 45 
training [3,4], while injuries to the superficial digital flexor tendon account for up to 46% of limb 46 
injuries, which are in turn responsible for 76% of all injuries sustained during Thoroughbred horse 47 
races [5]. The limited intrinsic capacity for self-repair, particularly in adults, makes treatment of 48 
cartilage defects challenging [6], and while tendons will eventually heal given careful management, 49 
the repaired tissue is functionally inferior and predisposes to reduced performance and high re-50 
injury rates [7]. The economic and welfare costs of these performance-related injuries in horses 51 
have stimulated interest in stem cell-based regenerative medical techniques to accelerate and 52 
improve healing. Indeed, mesenchymal stem cells (MSC) are already used clinically in horses in an 53 
attempt to improve both cartilage and tendon repair following injury [8,9]. In addition, because of 54 
the similarities in size, load and types of injury suffered to joints in horses and humans, a recent 55 
FDA report concluded that the horse was the most appropriate model animal for testing and 56 
monitoring clinical effects of new therapies for certain types of joint injury in man [10]. This paper 57 
briefly reviews the current state of stem cell therapies in the horse, and the potential role for and 58 
limitations associated with the isolation and characterization of equine embryonic stem cells. 59 
 60 
2. Current equine stem cell therapies 61 
 62 
Mesenchymal stem cells (MSC) are the local, multipotent precursors of connective tissues 63 
such as muscle, fat, tendon, ligament, bone and cartilage [11]. Their ability to self-renew and to 64 
differentiate into the respective tissues of interest means that they offer tremendous potential for 65 
equine regenerative medicine. Bone marrow-derived MSCs are currently the cell of choice for 66 
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treating cartilage or tendon injuries in horses [12]. In general, MSCs are recovered from bone 67 
marrow aspirates and part-purified by density gradient centrifugation and selective adhesion onto 68 
tissue culture plastic, and then expanded to confluent monolayers in vitro [12]. As conditions 69 
required for in vitro tenogenesis are poorly described, undifferentiated MSCs are currently injected 70 
directly into a tendon deficit [8,13].  For the treatment of cartilage injuries, MSCs can either be 71 
transplanted directly or differentiated into chondrocytes by pellet culture in chondrogenic medium 72 
containing serum, a mixture of growth factors (including TGFβ1, TGFβ3, BMP2, BMP4, BMP6, 73 
BMP7 or FGF2) and dexamethasone [4,9,14,15]. 74 
Preliminary studies in laboratory animals using MSCs for the treatment of tendon injuries 75 
have shown an improvement in collagen-fibre regeneration, histological appearance and mechanical 76 
function of tendon-like tissue [reviewed in 16]. By contrast, controlled scientific studies in horses, 77 
although limited in number, have shown no noticeable improvement in tendon structure or function 78 
compared to controls [8,13]. Studies using MSCs to treat articular cartilage injuries in rabbits, dogs 79 
and goats also report improvements in the quality of cartilage repair [reviewed in 9,12]. However, 80 
while treatment with autologous MSCs also appeared to improve cartilage repair in osteoarthritic 81 
knees of human patients, it did not yield significant clinical improvement [17]. Similarly in the 82 
horse, while MSCs improved the early healing response in articular cartilage lesions, it did not 83 
enhance long-term tissue repair over controls [9]. The latter authors concluded that the 84 
disappointing long-term results may be because MSCs are lost from the lesion over time, and they 85 
recommend that future efforts should be directed towards inducing differentiation into chondrocytes 86 
before implantation [9]. 87 
There are also technical limitations to the use of MSCs for the repair of cartilage and tendon. 88 
MSCs are scarce in bone marrow aspirates, require considerable time (~32 d) for expansion 89 
between isolation and implantation, and have a more limited potential for in vitro proliferation and 90 
targeted differentiation than cultured chondrocytes. In addition, bone marrow-derived adult MSCs 91 
are more difficult to isolate with increasing donor age and show reduced plasticity and growth as a 92 
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factor of both increasing donor age and number of in vitro passages [18-20]. On the other hand, the 93 
harvesting and auto-transplantation of expanded chondrocytes or tenocytes is not a viable option 94 
because two rounds of surgery would be required, and isolation of the cells required for expansion 95 
in culture may damage existing functional tissue. 96 
Embryonic stem cells (ESC) may offer a solution to the drawbacks encountered when using 97 
MSCs for tissue repair, since they offer virtually unlimited proliferation potential and longevity 98 
[21]. Isolated from the inner cell mass of blastocyst stage embryos, ESCs are truly pluripotent and, 99 
thus, able to give rise to all three germ layers of a developing embryo (endoderm, ectoderm and 100 
mesoderm) [22,23]. In addition, ESCs are amenable to genetic modification and differentiation into 101 
specific cell types or incorporation into chimeric animals, and thereby offer the potential for 102 
generating reporter cell lines or gain/loss of function disease models [24,25]. Such models would be 103 
invaluable to studies of the more than 189 genetic diseases described in the horse, of which 104 
approximately 95 have high homology with human genetic defects [1]; or to elucidate the 105 
underlying genetic causes of early embryonic death which is a source of considerable economic loss 106 
to the equine breeding industry [26]. Unlike MSCs, however, undifferentiated ESCs can not be used 107 
for direct transplantation because of the risk of teratoma formation [23]. Nevertheless, culture 108 
conditions have been described for the directed differentiation of human and mouse ESCs into both 109 
cartilage and, recently, tendon [27,28]. 110 
 111 
3. Progress in equine ESC isolation 112 
 113 
To date, the isolation and partial characterization of six putative equine ESC lines has been 114 
reported [29-31], although attempts to derive equine ESCs from in vitro produced embryos, or using 115 
interspecies somatic cell nuclear transfer, have so far been unsuccessful [32,33]. 116 
Saito et al. [29] microsurgically dissected the ICM from Day 6 to 7 in vivo blastocysts and 117 
then cultured the resulting cells for 3 to 5 d on bovine umbilical cord fibroblasts in MEM 118 
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supplemented with fetal calf serum and human LIF. ES-like cells were selected and passaged on 119 
fresh feeder layers every 6 to 7 d. Two out of the three ICMs (67%) cultured yielded ES-like cell 120 
lines which had a stable karyotype and maintained in vitro proliferation potential for more than 56 121 
passages (392 cell divisions; Table 1). The cells could be maintained without LIF and were positive 122 
for several stem-cell associated markers including octamer binding protein 4 (OCT4; also known as 123 
POU5F1), signal transducer and activator of transcription 3 (STAT3), alkaline phosphatase (AP), 124 
and stage-specific embryonic antigen 1 (SSEA1). These ES-like cells could also be induced to 125 
differentiate into neural precursors by culture in the presence of basic fibroblast growth factor 126 
(bFGF), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF); and into 127 
haematopoietic and endothelial precursors using bFGF, stem cell factor (SCF) and oncostatin M 128 
(OSM). 129 
In the study by Li et al. [30], the ICMs of Day 8 in vivo expanded blastocysts were dissected 130 
immunosurgically and then cultured for 7 d on mouse embryonic fibroblasts in DMEM/nut mix F12 131 
supplemented with fetal calf serum and human LIF. ES-like cells were then mechanically passaged 132 
on fresh mouse embryonic fibroblasts or horse fetal fibroblasts every 4 to 7 d. Approximately 33% 133 
of ICMs cultured in the presence of feeders and LIF yielded ES-like cell lines (n = 3) and a fourth 134 
cell line was derived in a follow-up study [31] (Table 1). In contrast to the ES-like cells produced 135 
by Saito et al. [29], however, both feeder cells and LIF were required to maintain cells in an 136 
undifferentiated state. Karyotype stability was not reported in this study but, after more than 26 137 
passages, cells were still positive for OCT4, STAT3, AP, SSEA1, SSEA4, Trafalgar-1-60 (TRA-1-60) 138 
and TRA-1-81. Removal of LIF and feeder layers from the in vitro culture medium resulted in the 139 
differentiation of the ES-like cells into neural ectoderm, visceral endoderm and cardiac and 140 
haematopoietic mesoderm. In contrast to human ESC controls, however, the four lines of equine 141 
ES-like cells did not form teratomas when injected into the testes of immunocompromised mice. 142 
Compared to most other large domestic species [34], isolation of ES-like cells from in vivo 143 
horse blastocysts therefore appears to be relatively straightforward. All six cell lines described 144 
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above exhibited ESC-like characteristics such as longevity, expression of stem cell-associated 145 
markers and in vitro pluripotency (Table 1). On the other hand, the absence of any data verifying in 146 
vivo pluripotency of the cells (e.g. teratoma or chimera formation) means that the cells cannot yet be 147 
definitively classified as ESCs. Li et al. [30] suggested that the failure of their equine ES-like cells 148 
to generate teratomas in an immunoprivileged site may be a peculiarity of equine ESCs. Certainly, 149 
the failure of teratoma formation is difficult to explain given that murine and primate ESCs, porcine 150 
ES-like cells, and bovine and porcine pluripotent ICM all yield teratomas under similar conditions 151 
[22,23,35-37]. Equine ICM transplantation experiments may help to determine whether this 152 
anomaly really is due to a peculiarity of equine pluripotent cells, or because the ES-like cells tested 153 
were not true ESCs. In this latter respect, it is possible that sub-optimal culture conditions for the 154 
equine ES-like cells led to a loss of pluripotent potential over time. Indeed, murine ESCs have been 155 
reported to lose their ability to generate pure ESC-derived offspring, or contribute to the germ line 156 
in chimeras, with increasing passage number [reviewed in 38]. The equine cells used in Li et al.’s 157 
teratoma trials were between passage 14 and 26 [30], by which time culture-induced changes could 158 
have reduced their in vivo pluripotent potential. It has also been reported that even recently isolated 159 
murine epiblast SCs, which closely resemble human ESCs, are unable to form chimeras, or do so 160 
with poor efficiency, just like ES-like cells from large domestic species [39-41]. In short, it appears 161 
that ES-like cells derived from the epiblast of a range of domestic species, which may include the 162 
horse, have more restricted pluripotent potential than true ESCs, and the current putative equine 163 
ESCs could quite conceivably actually be epiblast SCs. 164 
Sub-optimal culture conditions can also inadvertently select and enrich an alternative SC 165 
line. In ungulates, trophectoderm and primitive endoderm can outgrow cultured ICM even after 166 
careful dissection or immunosurgery, while these cells can still form embryoid-like bodies 167 
reminiscent of those formed by ESCs [34]. In addition, epithelial cells grown on fibroblast feeder-168 
layers can both look ES-like and be AP positive [34], while even multipotent (murine) adult 169 
progenitor cells have been shown to be able to differentiate into endoderm, ectoderm and mesoderm 170 
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[42]. Currently, our understanding of the processes controlling pluripotency in equine cells is both 171 
rudimentary, and based on the assumption that they will be comparable to those described for mice 172 
or man. Reliable markers or cell behaviour tests for the pluripotent state are clearly required both to 173 
definitively characterise existing lines of equine ESCs and to advance our understanding of how to 174 
manipulate cellular differentiation in equine cells. Moreover, without these markers, attempts to 175 
derive new cell lines or improve culture conditions will be impaired because any culture-induced 176 
changes that alter their pluripotent potential will go undetected. 177 
 178 
4. Problems with existing pluripotency markers in domestic species 179 
 180 
A golden rule in the characterisation of ESCs is that their behaviour should recapitulate what 181 
occurs naturally in vivo [21]. Likewise, markers for pluripotency in ESCs should only be expressed 182 
in cells destined to form the embryonic ICM. SSEA1, SSEA3 and SSEA4 are all cell surface 183 
antigens associated with pluripotent stem cells, but their precise functions in the maintenance of 184 
pluripotency is not known. Furthermore, none of these markers can be used in isolation as a cross-185 
species definitive indicator of pluripotency because there are considerable between species 186 
differences in their expression in both ESCs and embryos. For example, SSEA1 is expressed in 187 
mouse but not human ESCs [22,23], SSEA3 is expressed in human ESCs and horse embryos but not 188 
horse ES-like cells [23,31], and the expression of SSEA4 differs between horse ES-like cell lines 189 
[29,31] (Table 1). Moreover, SSEA1 and SSEA4 proteins are not confined to the ICM of caprine 190 
embryos but are also expressed in the trophectoderm [43]. TRA-1-60 and -81 are also cell surface 191 
antigens that recognize different epitopes of a common glycoprotein of which the exact function is 192 
not yet known [44]. Furthermore, while AP staining is also widely used to characterise ESCs it is 193 
neither ESC nor ICM-specific, since it also labels other stem cell types and is expressed at different 194 
times by either the epiblast or trophectoderm [34,45,46]. 195 
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Even genes for which a function in the maintenance of pluripotency has been validated 196 
using knockout mouse models often have different expression patterns in other species. In the 197 
mouse, Oct4 is known to specify the ICM while Nanog specifies the pluripotent epiblast; both are 198 
therefore restricted to the ICM in expanded murine blastocysts [47-49]. By contrast, OCT4 protein 199 
is strongly expressed in both the ICM and trophectoderm of human, primate, bovine, caprine and 200 
porcine blastocysts [43,48,50-52], but also primitive endoderm cell lines [34]. Moreover, both 201 
NANOG mRNA and protein appear to be completely absent during the period of ICM and epiblast 202 
formation in the pig [51], while in primate blastocysts, NANOG rather than OCT4 has been 203 
proposed to specify the ICM [52]. 204 
The different expression of OCT4 and NANOG in species other than the mouse, suggests 205 
that there are species-specific differences in genes regulating pluripotency and early lineage 206 
segregation which may reflect differences in embryonic development. In the pig and cow, for 207 
example, prolonged OCT4 expression in the trophectoderm has been proposed to be necessary for 208 
rapid proliferation of the trophectoderm during embryonic elongation on Days 11 to 12 after 209 
fertilization [48,51]. Differences in the form of, and mechanisms underlying embryogenesis and 210 
placental development may also partly explain why the derivation of embryonic stem cells has 211 
proven so difficult in many large domestic species [34]. In short, accepted murine ESC markers 212 
may not be appropriate to other species, and a species-specific approach is likely to be necessary to 213 
validate adequate markers of pluripotency. 214 
 215 
5. Pluripotency markers in equine embryos 216 
 217 
Since early equine embryogenesis differs significantly to that of the mouse, pig, cow and 218 
human [34,53], it is reasonable to anticipate different temporal and spatial expression patterns for 219 
putative pluripotency genes in the horse. The genome of the early equine embryo is thought to 220 
activate at the 4 to 8 cell stage, i.e. during the prolonged 6 d migration through the oviduct [54]. 221 
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When the embryo enters the uterus on Day 6, it is at the compacted morula stage, but within a few 222 
hours has developed into an early blastocyst with the first clearly visible signs of trophectoderm and 223 
ICM differentiation [53,55]. At around the same time, a unique glycoprotein tertiary embryonic coat 224 
(the ‘blastocyst capsule’) forms between the trophectoderm and zona pellucida; it remains in place 225 
until around Day 21 and is essential for the continuation of pregnancy [56]. After segregation of the 226 
ICM into epiblast and hypoblast on around Day 8 primitive endoderm forms as separate colonies 227 
distributed sporadically over the interior of the trophoblast, which then expand and coalesce [57]. 228 
The next microscopically visible evidence of a major cell differentiation event, gastrulation, 229 
commences on Day 11 to 12 with the appearance of the primitive streak and the first discernable 230 
mesoderm cells [57,58]. Unlike porcine and bovine conceptuses, the pre-implantation equine 231 
conceptus remains spherical (i.e. it does not elongate) and highly mobile, migrating continuously 232 
throughout the uterus until approximately Day 16, a process that is essential to maternal recognition 233 
of pregnancy [59]. The trophectoderm first makes direct physical contact with the endometrium as 234 
late as Day 22 to 23, following dissolution of the blastocyst capsule and, at around Day 35, a 235 
specialized band of trophectoderm cells invades the endometrium to establish the temporary, eCG-236 
secreting endocrine organs, the endometrial cups. True placental formation (i.e. trophectoderm-237 
endometrium interdigitation) does not start until as late as Day 40 of gestation, and is then of the 238 
non-invasive epitheliochorial type [60]. 239 
It is quite conceivable that the various idiosyncrasies of early equine conceptus development 240 
profoundly affect the pattern of gene expression within the various cell lineages of the conceptus. 241 
However, the genes regulating pluripotency and early lineage segregation in the horse have yet to 242 
be fully described. To date, just three studies have reported the (changes in) expression or ICM-243 
specificity of putative pluripotency markers in early horse embryos [31,33,61] (Table 2). Hinrichs et 244 
al. [33] reported that OCT4 protein was expressed in the cytoplasm and nucleus of immature 245 
oocytes and that the level of expression decreased gradually during the first 4 d of in vitro culture in 246 
embryos produced by ICSI, before increasing again in the cell nuclei during Days 5 to 7, 247 
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presumably as a result of embryonic genome activation. Interestingly, OCT4 protein was found in 248 
both the ICM and trophectoderm of Day 7 to 10 blastocysts and lost from the trophectoderm of in 249 
vitro embryos larger than 1 000 µm in diameter only if they had been exposed to the uterine 250 
environment for 2 to 3 d by embryo transfer [33]. For in vivo Day 7 to 10 blastocysts, OCT4 protein 251 
expression was strong in the ICM and weak in the trophectoderm, and completely confined to the 252 
ICM of embryos exceeding 600 µm in diameter. AP staining was similarly stronger in the ICM than 253 
in the trophectoderm [31,33]. Our own studies suggest that OCT4 mRNA expression decreases 254 
successively during the morula to early blastocyst and the early to expanded blastocyst transitions, a 255 
pattern consistent with a role in ICM specification. We also recorded down-regulation of NANOG 256 
mRNA, but only at the early to expanded blastocyst transition, a pattern that fits a role in 257 
specification of the epiblast [61]. These preliminary findings need however to be confirmed at the 258 
level of protein expression and distribution. Similar to the situation for OCT4, proteins of the 259 
pluripotency-associated cell surface markers SSEA1, SSEA3, SSEA4, TRA-1-60 and TRA-1-81, 260 
were found to be expressed throughout both the ICM and trophectoderm of Day 7 blastocysts [31] 261 
(Table 2), raising similar questions as to their suitability as pluripotency markers. 262 
During morula to expanded blastocyst development in the horse, there is a rapid increase in 263 
cell number from 160 to over 2 900 that occurs predominantly in the trophectoderm [62]. As in the 264 
pig and cow, the dramatic proliferation of trophectoderm cells may explain the prolonged 265 
expression of OCT4 in this tissue. The even more prolonged expression of OCT4 by trophectoderm 266 
of in vitro horse embryos may reflect the significant retardation of development that appears to 267 
occur under these conditions [63], and may partially explain why deriving ESCs from this source 268 
has proven difficult [33]. It is possible that a similar delayed down-regulation in trophectoderm 269 
cells until the horse embryo exceeds a threshold size or developmental stage also applies to other 270 
pluripotency markers, although this remains to be tested. Certainly, it appears that the panel of 271 
markers used to characterise pluripotency and ESCs in the horse to date are inadequate. 272 
 273 
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6. Where to from here? 274 
 275 
Identification and validation of embryonic stem cells and indeed understanding of the 276 
molecular conditions required for pluripotency in domestic species such as the horse requires a 277 
reliable set of molecular markers proven to be both specific and exclusive to the pluripotent cells of 278 
the developing embryo. Since the details of embryogenesis differ markedly between species, the 279 
exact determinants of pluripotency may also vary; such studies should therefore be carried out on a 280 
per species basis. Nevertheless, recent work to define the interaction networks controlling 281 
pluripotency in mouse and human ESCs has provided a useful list of candidate genes to evaluate in 282 
other species [64,65]. We have been using just this type of information to examine the expression of 283 
potential pluripotency-associated genes in equine embryos and have found that factors such as 284 
growth and differentiation factor 3 (GDF3), developmental pluripotency-associated 4 (DPPA4) and 285 
telomerase reverse transcriptase (TERT) are down-regulated during the morula to early blastocyst 286 
transition [61]. The time-course of mRNA expression for these genes therefore suggest that they 287 
may be useful markers for pluripotency, and whole mount immunofluorescent studies are ongoing 288 
to examine the ICM-specificity of these, and other candidate, genes at the protein level. In addition 289 
to this candidate-gene ‘bottom-up’ approach, newly emerging molecular tools such as equine-290 
specific microarrays will enable a ‘top-down’ approach to examine comparative global gene 291 
expression profiles in equine embryos and putative ESCs and thereby identify a wide array of genes 292 
with potential roles in sustaining or terminating pluripotency. 293 
Once defined, a suitable panel of pluripotency markers could be used to further characterise 294 
existing equine ES-like cells [29-31], and to assist in the establishment and validation of newly 295 
derived pluripotent cell lines. Moreover, understanding the molecular mechanisms regulating 296 
pluripotency in the horse will permit more detailed classification of the diverse range of stem cells 297 
currently used in equine regenerative medicine; an analogous process was recently initiated for 298 
human regenerative medicine [65]. 299 
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For some domestic species, optimizing specific culture conditions that maintain 300 
pluripotency is likely to be critical to successfully establishing ESCs. In the pig and cow, for 301 
example, primary epiblast cells can only be cultured on STO feeder cells, are highly sensitive to 302 
lysis and rapidly differentiate within 48 to 96 h [38]. By contrast, the isolation of ES-like cells from 303 
cultured ICM appears to be more robust and efficient in the horse [29,30]. There is, however, still a 304 
need to optimize culture conditions for equine ES-like cells (by determining optimal media, feeder 305 
cells and cytokine requirements) to avoid culture-induced changes that may compromise indices of 306 
cellular pluripotency, such as teratoma forming ability. In this respect, reliable markers would 307 
permit the monitoring of pluripotency state during culture. Although beyond the scope of this 308 
review, alternative cell types, such as embryonic germ cells (EGCs) may overcome problems of 309 
limited in vivo pluripotency in equine ES-like cells, as has been demonstrated for porcine and 310 
bovine EGCs [reviewed in 41]. 311 
A potential advantage of ESCs is ‘off the shelf’ use for allogenic transplantation. However, 312 
if they are to be used in this way, it is important to examine the likely immunogenicity of these cells 313 
and their derivatives. Transplantation rejection is governed primarily by MHC antigens and there 314 
are indications that some ESC derivatives do not express some MHC antigens and/or have other 315 
characteristics that help them avoid rejection [66,67]. If equine ESCs do not show reduced MHC 316 
expression, alternative technologies such as somatic cell nuclear transfer-derived ESCs and induced 317 
pluripotent stem (iPS) cells may offer ways of generating ‘disease-specific’ or ‘patient-specific’ 318 
pluripotent cells. Indeed, patient-specific genetic defects have already been treated by a 319 
combination of iPS, cell and gene therapy technologies in the mouse [68], while the recent report of 320 
iPS generation from porcine cells [69] suggests that derivation of similar pluripotent cells may soon 321 
be possible for the horse. 322 
 323 
7. Conclusion 324 
 325 
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Due to their unlimited potential for proliferation and ability to differentiate into all three 326 
germ layers, embryonic stem cells offer tremendous potential for regenerative therapy of tissues 327 
with a limited capacity for self-repair. However, it is clear that (i) existing equine ES-like cells are 328 
not yet fully characterised, and (ii) current markers used to characterise pluripotency in equine cells 329 
are inadequate. Establishing a panel of validated pluripotency markers specific to the horse should 330 
simplify future attempts to identify, isolate, characterise, and classify equine pluripotent stem cells 331 
derived either from embryos or from other tissues, e.g. by iPS technology. 332 
 333 
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 Tables 580 
Table 1: Characteristics of the six reported equine embryonic stem cell lines. 581 
 Saito et al. [29] Li et al. [30]; Guest and Allen [31] 
origin Day 6 to 7 in vivo blastocysts Day 8 in vivo expanded blastocysts 
number of cell lines 2 4 
feeder layer bovine umbilical cord fibroblasts mouse embryonic or horse fetal fibroblasts 
maintenance feeders only feeders + LIF 
karyotype normal (at passage 20) not reported 
longevity >56 passages (392 cell divisions) >26 passages 
OCT4 + + 
STAT3 + + 
AP + + 
SSEA1 + + 
SSEA3 - - 
SSEA4 - + 
TRA-1-60 not reported + 
TRA-1-81 not reported + 
in vitro pluripotency ectoderm, mesoderm ectoderm, endoderm and mesoderm 
in vivo pluripotency not reported - 
 582 
 583 
Table 2: Localized protein expression for pluripotency-associated markers in Day 7 to 10 584 
equine blastocysts [31,33]. 585 
 inner cell mass trophectoderm 
OCT4 ++ +/- 
STAT3 not reported not reported 
AP +++ + 
SSEA1 ++ ++ 
SSEA3 ++ ++ 
SSEA4 ++ ++ 
TRA-1-60 +++ + 
TRA-1-81 +++ + 
+++, ++, + and -: strong, intermediate, weak and no expression respectively 
 586 
